NCT01813214View on ClinicalTrials.gov

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

December 31, 2016

Conditions
Melanoma
Interventions
DRUG

Vemurafenib

DRUG

Cobimetinib

Trial Locations (4)

20007

Georgetown Lombardi Comprehsnive Cancer Center, Washington D.C.

22903

University of Virginia Health System, Charlottesville

77030

University of Texas MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Melanoma Research Alliance

OTHER

lead

Georgetown University

OTHER